Apremilast psoriasis fda. Earlier this year, the U.

Apremilast psoriasis fda. 1)]. for pediatric use. FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis Potential to Be First and Only Approved Oral Therapy for the Mild-to-Moderate Patient Population Acceptance Based on Data From Phase 3 ADVANCE Study, Demonstrating Clinically Meaningful Improvements Through Week 32 FDA Action Date Set for December 19, 2021 clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination half-life of approximately 6-9 hours. 2 Plaque Psoriasis Apremilast tablets are indicated for the treatment of: Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. 20, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced Otezla ® (apremilast) is now available in the U. and oral ulcers associated with Behçet's Disease. Dec 20, 2023 · The Food and Drug Administration (FDA) approved Otezla for the treatment of the most common form of psoriasis, known as plaque psoriasis, in adult patients who are candidates for phototherapy or Apremilast is FDA approved for treating psoriatic arthritis in adult patients with moderately to severely active disease, plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy, and adults with Behcet disease associated with oral ulcers. Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet's Disease. com Safety and effectiveness Before receiving approval from the US Food and Drug Agency (FDA), apremilast was studied in more than 4,000 adults with plaque psoriasis, psoriatic arthritis, or both. In July 2019, apremilast was also approved by the FDA for treatment of mouth ulcers associated with Behçet disease. Few patients with plaque psoriasis stopped taking apremilast due to side effects. ESTEEM trials FDA approval for moderate-to-severe plaque psoriasis was based on results from the ESTEEM trials. Food and Drug Administration (FDA) extended the approval of Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy, now including those individuals who have mild or moderate plaque psoriasis severity. 3 Apremilast is the first and only oral medication approved in the US for young patients with severe plaque May 6, 2021 · After data from a phase 3 study, FDA opens potential for apremilast to be the first and only approved oral therapy for mild to moderate plaque psoriasis. The Drug The approval for the oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) specific for cyclic adenosine monophosphate (cAMP) was awarded to clearance of apremilast is about 10 L/hr in healthy subjects, with a terminal elimination half-life of approximately 6-9 hours. Indications and Usage for Apremilast 1. The drug is commonly used to treat diseases such as psoriatic arthritis (PsA), Behcet’s Syndrome, and plaque psoriasis. Although its efficacy and safety have been well established in clinical studies, in real-world settings, different Dec 20, 2021 · FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL Otezla is the First and Only Oral Therapy Approved in Adult Patients with Mar 25, 2022 · New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis Real-world evidence data being presented demonstrates continued burden of disease for patients with mild to moderate plaque psoriasis Otezla is the first and only oral therapy FDA approved in adult patients with plaque psoriasis across all severities Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of psoriasis and psoriatic arthritis. Food and Drug Administration (FDA) approved Otezla for the treatment of moderate to severe plaque psoriasis Co-administration of the CYP450 inducer rifampin (600 mg once daily for 15 days) with a single oral dose of 30-mg apremilast resulted in reduction of apremilast AUC and Cmax by 72% and 43%, respectively [see Warnings and Precautions (5. Dec 26, 2024 · Apremilast Now Available for Pediatric Use in the US This marks a significant development for young patients with psoriasis as there are currently no other FDA-approved oral medications for the condition. Mar 25, 2022 · New data further reinforces clinical benefit of Otezla in mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis Real-world evidence data being presented demonstrates continued burden of disease for patients with mild to moderate plaque psoriasis Otezla is the first and only oral therapy FDA approved in adult patients with plaque psoriasis across all severities May 7, 2024 · PDE-4 inhibitors, like apremilast, treat psoriasis by reducing inflammation and suppressing the immune response, improving skin symptoms. Supplied by Celgene Corporation This Prior Approval supplemental new drug application provides for changes to the Indication and Usage, and Clinical Studies sections of the labeling to include data for subjects with mild to moderate plaque psoriasis, and to allow for an expansion of the indication to include adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. The pediatric approval was supported by data from the randomized, double-blind, placebo-controlled SPROUT trial Pediatric Patients 6 Years of Age and Older and Weighing at Least 20 kg with Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis See Table 2 for the initial titration schedule (2. This review will discuss the basic mechanisms of the disease known as psoriasis, as well as the mode of operation, pharmacological properties, clinical trials, and pharmacokinetics of apremilast, particularly in relation to nanocarrier modification of this promising drug. Food and Drug Administration (FDA) for the treatment of psoriasis and psoriatic arthritis (PsA). Emphasis is placed on safety evaluations, although efficacy considerations are also addressed. 10 Since Food and Drug Administration (FDA) approval in 2014, apremilast has demonstrated a favorable Food and Drug Administration Dec 20, 2021 · A Phase 3, multicenter, open-label study to assess the safety of apremilast in approximately 50 pediatric subjects (6 through 17 years of age, inclusive) with mild-to-moderate plaque psoriasis Aug 20, 2024 · First and Only Pill for Children and Adolescents Ages 6-17 with Moderate to Severe Plaque Psoriasis THOUSAND OAKS, Calif. Dec 22, 2021 · On December 21, 2021, the U. with an approved indication for the treatment of PsA. Introduction Apremilast (Otezla®, Celgene) is an oral small- molecule inhibitor of the enzyme phosphodiesterase 4, which plays an important role in chronic inflammation associated with psoriasis. Aug 26, 2024 · Apremilast (Otezla; Amgen Inc) is currently available in the US for the treatment of moderate to severe plaque psoriasis among children and adolescents aged 6 to 17 years following its FDA approval that was granted earlier this year. Pediatric Patients 6 Years of Age and Older and Weighing at Least 20 kg with Psoriatic Arthritis or Moderate to Severe Plaque Psoriasis The recommended dosage for pediatric patients 6 years of age and older and weighing at least 20 kg with psoriatic arthritis or moderate to severe plaque psoriasis is based on body weight. Earlier this year, the U. The Food and Drug Administration (FDA) has expanded the approval of Otezla Sep 30, 2025 · Otezla (apremilast) is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Feb 17, 2021 · The US Food and Drug Administration (FDA) has approved apremilast (Otezla), commonly used to treat diseases such as psoriatic arthritis (PsA), Behcet’s Syndrome, and plaque psoriasis, as a generic drug in 10, 20, and 30 mg tablets. Jul 30, 2025 · In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and adolescents with moderate to severe plaque psoriasis. Avoid the use of OTEZLA in patients with known hypersensitivity to apremilast or to any of the excipients in the sensitivity reactions develop during treatment, discontinue OTEZLA and institute appropriate •Diarrhea, Nausea, and Vomiting: Consider OTEZLA dose reduction or suspension This article provides an update on the use of oral apremilast, a phosphodiesterase-4 (PDE4) inhibitor, for the treatment of plaque psoriasis. Of those who stopped, the most Apremilast, a unique oral phosphodiesterase 4 inhibitor that immunomodulates the inflammatory response, is internationally approved for use in adults with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Of those who stopped, the most Aug 20, 2024 · Otezla is the first oral therapy approved for moderate to severe plaque psoriasis in this patient population. Both Dec 27, 2024 · Otzela ® (apremilast): Plaque Psoriasis On April 25, 2024, the FDA expanded the approval of apremilast to include treatment of pediatric patients aged 6 years and older weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Apremilast is FDA approved for treating psoriatic arthritis in adult patients with moderately to severely active disease, plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy, and adults with Behcet disease associated with oral ulcers. NDA 205437/Efficacy Supplement S-013 Multi-disciplinary Review and Evaluation OTEZLA (apremilast) oral tablets, 20 mg and 30 mg Feb 19, 2025 · Amneal Pharmaceuticals NY LLC: Apremilast, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Otezla is the first and only INDICATIONS AND CLINICAL USE Plaque Psoriasis MINT-APREMILAST (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Following oral administration of radio-labeled apremilast, about 58% and 39% of the radioactivity is recovered in urine Mar 8, 2022 · Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor, which elevates cAMP levels to regulate the inflammatory response responsible for psoriasis. INTRODUCTION This review documents the Division of Risk Management (DRISK) evaluation of the New Drug Application (NDA) 205437 for Otezla (apremilast) tablets, to assess the need for a Risk Evaluation and Mitigation Strategy (REMS). Apremilast is also used off-label for various dermatologic Dec 20, 2021 · Otezla ® (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Dec 22, 2021 · The FDA has approved apremilast (Otezla, Amgen) for adult patients with plaque psoriasis who are candidates for either phototherapy or systemic therapy. Apremilast, an oral phosphodiesterase-4 inhibitor, is approved for use in the management of psoriasis and psoriatic arthritis. Feb 17, 2021 · The US Food and Drug Administration (FDA) has granted approval for the first generic version of Otezla (apremilast) in 10, 20, and 30 mg tablets. Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. [25] Mar 20, 2023 · Abstract: Psoriasis is a chronic inflammatory skin condition resulting from the dysregulation of cytokines. This announcement follows the recent US Food and Drug Administration (FDA) expanded Otezla label approval which enabled the use of Otezla across all levels of disease severity. Apremilast (Otezla ®, Celgene Corporation, Summit, NJ, USA) is an orally available phosphodiesterase 4 (PDE4) inhibitor approved by the US Food and Drug Administration (FDA) in March 2014 for the treatment of active PsA in adults, and in September 2014 for the treatment of moderate to severe plaque psoriasis in patients who are candidates for Dec 23, 2021 · With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe. Sep 23, 2014 · The US Food and Drug Administration (FDA) has approved apremilast (Otezla, Celgene) for treating patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic Mar 25, 2025 · FDA Approves First Oral Treatment for All Psoriasis Severities Apremilast has been approved for mild-to-moderate psoriasis severity. Apremilast, an oral phosphodiesterase-4 inhibitor, is approved by the Federal Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in patients who are eligible for phototherapy or systemic therapy. Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplant … Otezla® is a pill that helps treat symptoms of plaque psoriasis (PsO), psoriatic arthritis (PsA), and oral ulcers in Behçet’s Disease (BD). In these trials, 1257 patients with moderate-to-severe plaque psoriasis were randomized 2:1 to apremilast 30 mg twice daily (after a titration period) or placebo. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. Aug 23, 2024 · On August 20, 2024, Amgen announced that Otezla ® (apremilast) is now available in the U. Apremilast received US Food and Drug Administration (FDA) approval in 2014 for treatment of moderate-to-severe plaque psoriasis in adults who are candidates for phototherapy or systemic therapy. It is a small molecule phosphodiesterase 4 (PDE4) inhibitor. , Aug. 's Otezla (apremilast) Tablets. 12 Subsequently, Celgene received FDA approval in September 2014 to further market the drug for the treatment of moderate-to-severe plaque History Apremilast was approved by the US Food and Drug Administration (FDA) in 2014, for treatment of adults with active psoriatic arthritis and moderate to severe plaque psoriasis, and approved in 2019, for oral ulcers associated with Behçet's disease. Apremilast is an oral selective phosphodiesterase-4 inhibitor developed recently for psoriasis treatment. Jul 15, 2024 · FDA approval history for Otezla (apremilast) used to treat Psoriatic Arthritis, Plaque Psoriasis, Behcet's Disease. FDA Accepts Roflumilast Foam sNDA for Scalp and Body Psoriasis Apremilast is a PDE4 inhibitor approved by the FDA for the treatment of moderate-severe plaque psoriasis in 2014 [7,28]. FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis Potential to Be First and Only Approved Oral Therapy for the Mild-to-Moderate Patient Population Acceptance Based on Data From Phase 3 ADVANCE Study, Demonstrating Clinically Meaningful Improvements Through Week 32 FDA Action Date Set for December 19, 2021 Apremilast demonstrated efficacy in mild-to-moderate psoriasis and safety consistent with the established safety profile of apremilast. The application for Otezla (apremilast), a new molecular entity (NME), was submitted to the Division of Pulmonary and Rheumatology Products (DPARP) by Celgene Feb 23, 2025 · Introduction: Apremilast and deucravacitinib are oral small-molecule inhibitors approved for the treatment of psoriasis, each with the potential to fill unmet needs among psoriasis patients. The sponsor proposed that the ability of CC-10004 to modulate levels of pro- and anti-inflammatory mediators will provide therapeutic benefit in psoriasis patients. The approval marked apremilast as the first approved medication to treat this patient population, according to study authors. The aim of this study is to assess the real-life outcomes of use of apremilast in patients with psoriasis in everyday clinical practice. 1) Apr 28, 2014 · Apremilast (Otezla ®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). Most of the side effects that patients experienced during clinical trials were mild. Apremilast (APR) (OTEZLA®) was approved on March 21, 2014 for the treatment of psoriatic arthritis in adults (NDA 205437). Although its efficacy and safety have been well established in clinical studies, in real-world settings, different Apremilast (APR) (OTEZLA®) was approved on March 21, 2014 for the treatment of psoriatic arthritis in adults (NDA 205437). (1 Oct 18, 2024 · New Treatment for Pediatric Psoriasis Amgen recently announced that apremilast is now available in the US for pediatric patients 6 years and older with moderate to severe plaque psoriasis. Pediatric use information is approved for Amgen Inc. Additionally, a , apremilast was administered at doses of 250, 500, or 750 mg/kg/day to dams during organogenesis (gestation Day 6 through 15). If apremilast works for you, you should start to notice the benefits within four months of starting the treatment. Apr 5, 2022 · New data presented by Amgen at the 2022 AAD Congress reinforced the efficacy of apremilast in patients with mild to moderate plaque psoriasis and in patients with palmoplantar pustulosis. 1 Sep 30, 2025 · Apremilast is used to treat psoriatic arthritis, psoriasis. 1. This page provides convenient, at-a-glance highlights from the full guidelines, providing dermatologists with the most important clinical information. Dec 20, 2021 · FDA APPROVES OTEZLA® (APREMILAST) FOR THE TREATMENT OF ADULT PATIENTS WITH PLAQUE PSORIASIS, REGARDLESS OF SEVERITY LEVEL Otezla is the First and Only Oral Therapy Approved in Adult Patients with May 7, 2024 · PDE-4 inhibitors, like apremilast, treat psoriasis by reducing inflammation and suppressing the immune response, improving skin symptoms. Apremilast (Otezla^®) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast was previously approved for treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy as well as treatment of adults with active psoriatic arthritis and treatment of adults with oral ulcers associated with Behcet’s disease. The FDA has approved Otezla (apremilast) to treat adults with plaque psoriasis across all severities, including mild, moderate, and severe. Safety and effectiveness Before receiving approval from the US Food and Drug Agency (FDA), apremilast was studied in more than 4,000 adults with plaque psoriasis, psoriatic arthritis, or both. It is approved in multiple countries worldwide, including the USA and those of the EU, for the treatment of adults with psoriatic arthritis, plaque psoriasis, or oral ulcers associated with Behçe … Dec 23, 2021 · With this expanded indication, apremilast (Otezla; Amgen) is now the first and only oral treatment approved in adult patients with plaque psoriasis across all severities, including mild, moderate, and severe. Includes Otezla side effects, dose, interactions and indications. Hypersensitivity: Cases of angioedema and anaphylaxis have been reported during post marketing surveillance. Otezla® (apremilast)/Otezla XR™ (apremilast) is indicated for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. Otezla is indicated for the treatment of adult patients with active psoriatic arthritis. Amgen has announced the availability of apremilast (Otezla) in the Following oral administration of radio-labeled apremilast, about 58% and 39% of the radioactivity is recovered in urine and feces, respectively, with about 3% and 7% of the radioactive dose recovered as apremilast in urine and feces, respectively. Apremilast is also used off-label for various dermatologic Apr 29, 2025 · Read on for Otezla (apremilast) for psoriasis dosage information, including typical dosage, adjustments for health conditions, and what to do if you miss a dose. Read the article below for more information. Abstract Apremilast is an orally administered small molecule that specifically inhibits the phosphodiesterase-4 enzyme and modulates the immune system by increasing the levels of intracellular cyclic adenosine monophosphate (cAMP) and inhibiting IL-2 & 8, interferon-γ and tumor necrosis factor (TNF) production. Following oral administration of radio-labeled apremilast, about 58% and 39% of the radioactivity is recovered in urine and feces, respectively, with about 3% and 7% of the radioactive dose recovered as apremilast in urine and feces, respectively. But there is a lack of real-world studies on the safety of apremilast in large numbers of people. What is apremilast used for? In September 2014, the US Food and Drug Food and Drug Administration Aug 27, 2024 · The Food and Drug Administration (FDA) has expanded the approval of Otezla ® (apremilast) to include treatment of pediatric patients 6 years of age and older weighing at least 20kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. As reported in the clinical trials in this regard, this drug is administered orally at the dosage of 30 mg twice per day, and PASI 75 response has been attained in week 16 in 29–41% of psoriatic patients [28]. Apremilast showed certain efficacy in a human NK cell driven animal model of psoriasis. It is the first oral medication in the U. Aug 20, 2024 · Amgen announces new FDA-approved oral treatment option for children and adolescents with moderate to severe plaque psoriasis. 1 The treatment is intended for patients who are candidates for phototherapy or systemic therapy. Apr 23, 2022 · Apremilast is an immunosuppressant drug indicated for inflammatory disorders like psoriasis. 16 Medication class: Phosphodiesterase 4 inhibitor 4 days ago · Amgen has won FDA approval for a stronger label for its oral plaque psoriasis therapy Otezla, as it prepares for competition from Bristol-Myers Squibb's much-touted rival deucravacitinib, which Otezla ® (apremilast) is a prescription medicine used for the treatment of: Adult patients with plaque psoriasis for whom phototherapy or systemic therapy is appropriate. 1) For patients weighing 50 kg or more: Recommended maintenance dosage is OTEZLA 30 mg twice daily or OTEZLA XR 75 mg once daily (2. Limitations of Use: Apremilast has not been studied and is therefore not indicated in combination with other systemic (conventional or biologic) therapies or phototherapy for Aug 20, 2024 · Apremilast (Otezla) for the treatment of moderate to severe plaque psoriasis in children and adolescents aged 6 years and older who weigh at least 44 pounds is now available for use in the United States, biotechnology company Amgen announced in a release. A April 25, 2024 - The FDA approved Amgen’s Otezla (apremilast), for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. With this NDA, the same applicant has proposed an indication for the treatment of moderate to severe plaque psoriasis in adult subjects who are candidates for phototherapy or systemic therapy. NDA 205437/Efficacy Supplement S-013 Multi-disciplinary Review and Evaluation OTEZLA (apremilast) oral tablets, 20 mg and 30 mg Apr 7, 2025 · Abstract Apremilast, a unique oral immunomodulatory phosphodiesterase 4 inhibitor, has been approved by the U. Oct 21, 2024 · Otezla is a brand-name oral tablet prescribed for plaque psoriasis, psoriatic arthritis, and ulcers in certain people. Apremilast has been shown to reduce symptoms such as swollen and tender joints and to improve skin symptoms, including scalp and nail psoriasis. 3) and Drug Interactions (7. Otezla is indicated for the treatment of pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. A summary of these May 5, 2025 · Introduction Apremilast and deucravacitinib are oral small-molecule inhibitors approved for the treatment of psoriasis, each with the potential to fill unmet needs among psoriasis patients. Access information on the Academy's guidelines of care for psoriasis. It is FDA approved for the treatment of psoriasis, psoriatic arthritis, and oral Feb 26, 2025 · Full Prescribing Information 1. Otezla Approved By FDA for Psoriasis The United States Food and Drug Administration approved the medication Otezla (apremilast) for moderate to severe Plaque Psoriasis this Wednesday. S. Following oral administration in humans, apremilast is a major circulating component (45%) followed by inactive metabolite M12 (39%), a glucuronide conjugate of O-demethylated apremilast. 1 It was approved by the FDA in April 2024. The Food and Drug Administration (FDA) has expanded the approval of apremilast and included treatment of children 6 years of age and older weighing at least 20kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Includes apremilast side effects, interactions, and indications. In a combined fertility and embryo-fetal development study in mice, apremilast was ad. for the treatment of moderate to severe plaque psoriasis in children 6 years and older who weigh at least 20 kg (44 pounds) and are candidates for phototherapy or systemic therapy. Otezla XR These studies investigate the potential use of apremilast in the treatment of pediatric patients with moderate to severe plaque psoriasis who are candidates for systemic or phototherapy. Otezla contains the active ingredient apremilast and belongs to the disease FDA-Approved Indications Adult patients with plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy Jul 19, 2019 · With the indication, apremilast is now approved to treat moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, adult patients with active psoriatic arthritis, and adult patients with oral ulcers associated with Behçet’s Disease. 1 Otezla® is an oral medication which works by inhibiting phosphodiesterase 4 See full list on drugs. [22][23][24] Apremilast is taken by mouth. Investigating their adverse event (AE) profiles with post-marketing data is essential for optimizing patient care. See full prescribing & safety info. Apremilast (Otezla^®) is an inhibitor of phosphodiesterase-4 (PDE-4) being developed by Amgen. In March 2014, the Food and Drug Administration (FDA) approved apremilast (Otezla, Celgene Corporation), the first selective inhibitor of phosphodiesterase 4 (PDE4) indicated for adults with active PsA. nldzn s8omxi3c b4xga lc7j btyiljm st0 kse8 wm8 avskt cq3